Filters
Older patients (aged ≥65 years) with unresectable hepatocellular carcinoma (HCC) may derive greater survival benefit with an atezolizumab + bevacizumab combination compared with sorafenib, according to results of a subgroup analysis of the IMbrave150 trial presented at ESMO GI 2020.
Drinking coffee, tea, or soda may trigger gastroesophageal reflux, whereas water, juice, or milk does not, according to a study.
The population-mean heart-rate–corrected QT interval (QTc) in a cohort of patients with eating disorders is normal and varies by subtype, according to a study. Marked QTc prolongation only occurs in the presence of external factors, indicating that QTc prolongation is not intrinsic to eating disorders.
A single-port system is feasible in robot-assisted radical prostatectomy, with operative and perioperative outcomes similar to those of a multiport robotic approach, a study has shown.
Faecal microbiota transplantation (FMT) may be a viable treatment option for patients with severe alcoholic hepatitis (SAH), reports a study presented at the Digital International Liver Congress (ILC) 2020.
Triaging patients with pulmonary embolism (PE) using a strategy based on either the HESTIA criteria or the simplified Pulmonary Embolism Severity Index (sPESI) score guides decisions on whom to safely send home to receive outpatient care, according to the results of the HOME-PE* trial.
Trofinetide shows signals of activity against core fragile X syndromes, leading to improvements in communication, repetitive movements, and social avoidance, among others according to a new study.
Individuals hospitalized with arrhythmia may have an increased risk of in-hospital mortality if they have a history of alcohol abuse, according to a study presented at BCVS* 2020.
Patient apathy appears to be an important factor in determining the efficacy of interventions targeting cancer-related fatigue (CRF), reports a new study.
Patients with type 2 diabetes (T2D) who initiated SGLT2* inhibitors (SGLT2is) had better cardiovascular (CV) outcomes than those on DPP-4** inhibitors, shows the large, global, real-world study, CVD-REAL 2.
